Model-based approach to identify predictors of paclitaxel-induced myelosuppression in "real-world" administration.

In contrast, paclitaxel drug label shows that across multiple clinical trials with different paclitaxel‐containing regimens and type of cancer, the elderly tend to experience grade III/IV neutropenia more frequently than the younger group, however, this trend did not reach statistical significance in most studies. 20 Additionally, a prospective analysis conducted by the Cancer and Leukemia Group B demonstrated that the elderly showed statistically significant lower nadir ANC and higher incidence of grade III neutropenia in the elderly in univariate analysis but no further multiple regression analysis was conducted. 23 Based on this study and other studies, the association between age and paclitaxel‐induced myelosuppression is not well‐established and clinicians could potentially maintain the current practice in managing elderly patients receiving paclitaxel‐containing therapy.

also in 111,027 other papers